Aubrey de Grey

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

Retrieved on: 
Wednesday, January 29, 2020
Science, Cardiology, Stem cells, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, AgeX Therapeutics, Biogerontology, Life extensionists, Induced pluripotent stem cell, Michael D. West, Aubrey de Grey

AgeX Therapeutics, Inc. ( AgeX ; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeXs HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.

Key Points: 
  • AgeX Therapeutics, Inc. ( AgeX ; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with a Japanese biopharma company utilizing AgeXs HLA-G-based immunotolerance UniverCyteTM technology platform for the engineering of hypoimmunogenic (universal) cells.
  • The research program will evaluate the expression of UniverCyte on induced pluripotent stem cells (iPS cells) and the ability of those UniverCyte-modified iPS cells to evade immune responses and to differentiate into somatic cells.
  • AgeX hopes to announce further collaborations for research and product development utilizing its technology platforms in the coming months.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.

Novel therapeutic approach to cardiovascular disease from SENS Research Foundation flagship research program graduates from laboratory to the biotech world

Retrieved on: 
Thursday, November 14, 2019
Branches of biology, Regenerative biomedicine, Articles, Medicine, Immortality, Non-profit organizations based in California, SENS Research Foundation, Emerging technologies, Life extensionists, Aubrey de Grey, SRF, Regenerative medicine

Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease.

Key Points: 
  • Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease.
  • Underdog will take a classic pharmaceutical approach and use it to attack the root causes of cardiovascular disease, said Kope.
  • This is an historic moment for SENS Research Foundation, said Dr. Aubrey de Grey, co-founder and Chief Science Officer of SRF.
  • SENS Research Foundation is a 501(c)(3) nonprofit that works to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging.

Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board

Retrieved on: 
Tuesday, September 10, 2019
Demography, ChromaDex, Articles, Humans, Ageing, Aubrey de Grey, Life extension, Aubrey

BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board.

Key Points: 
  • BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board.
  • "We are thrilled to have two of the pioneering thinkers in the industry, Aubrey de Grey and Frank Jaksch, join our Advisory Board," said Greg Schmergel, Chairman at Yuva Biosciences.
  • "Their expertise will greatly contribute to the company's development of cutting-edge mitochondrial science to ease the effects of aging."
  • Frank L. Jaksch, Jr., the Co-Founder of ChromaDex, is biochemist with a track record for successfully licensing and bringing breakthrough science to the supplements industry.

AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany

Retrieved on: 
Thursday, March 21, 2019
Seniors, Stem cells, Health, Biotechnology, Medical devices, Pharmaceutical, Research, Diabetes, Consumer, Science, Life extensionists, Life extension, Aubrey de Grey, Immortality, Articles, BioTime

AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that the company will present in multiple sessions at Undoing Aging 2019 , March 28-30 in Berlin, Germany.

Key Points: 
  • AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that the company will present in multiple sessions at Undoing Aging 2019 , March 28-30 in Berlin, Germany.
  • with Aubrey de Grey, Ph.D., AgeXs VP, New Technology Discovery and Vadim Gladyshev, Ph.D., Professor of Medicine at Harvard Medical School.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Faith, Technology and the Future: Aubrey de Grey to keynote Christian Transhumanist Conference in Nashville

Retrieved on: 
Tuesday, August 14, 2018
Demography, Immortality, Gerontology, Culture, Ageing, Emerging technologies, Futurology, Life extension, Aubrey de Grey, SENS Research Foundation, De Grey, Aubrey

NASHVILLE, Tenn., Aug. 14, 2018 /PRNewswire/ --The first-ever Christian Transhumanist Conference will be held on Saturday, August 25, at Lipscomb University in Nashville, TN.

Key Points: 
  • NASHVILLE, Tenn., Aug. 14, 2018 /PRNewswire/ --The first-ever Christian Transhumanist Conference will be held on Saturday, August 25, at Lipscomb University in Nashville, TN.
  • The conference will be sponsored by the Christian Transhumanist Association (CTA), based in Nashville, which pursues a better conversation between religion and technology.
  • The keynote speaker will be Aubrey de Grey, a Cambridge researcher working to end aging, and create biological immortality through science.
  • Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation.